


IT STARTS WITH ONE

JUNE 3-6, 2019 • PHILADELPHIA • #BIO2019



Building a brighter future for
children: How will large pediatric
trial networks help to deliver safe,
effective medicines?


The Innovative Medicines Initiative (IMI) – Europe's partnership for health

IMI1: 2008-2013

€2 bn (\$2.4 bn)
59 projects

IMI2: 2014-2020

€3.3 bn (\$4 bn)
More ambitious
More open
Greater scope




IMI – Ecosystem for innovative collaborations

IMI is a **neutral platform** where **all involved** in drug development can engage in **open collaboration** on **shared challenges** in areas of **unmet medical needs**.

All partners needed to find transformative solutions to **reduce late stage attrition**, **speed patient access** and **improve health outcomes** and find solutions for a sustainable healthcare system

**Over 11 500
researchers from an
international, cross-
sector community**



Our panellists

Dr. Gerri Baer

Medical Officer, Neonatology Team Leader, Office of Pediatric Therapeutics, U.S. Food and Drug Administration

Dr. Sam Maldonado

Vice President, Head of Child Health Innovation and Leadership Department (CHILD), Johnson & Johnson

Dr. Annette Bakker

President, Children's Tumor Foundation